If you would like more information about the profile please click
. You will be directed to a new page where you will need
to provide some information about yourself/your business cooperation needs and submit
your expression of interest in the profile . A Network Partner will then contact
you to discuss your interest in greater detail.
A UK-based SME has developed a novel formulation of well-characterised chemical entities that renders cancer cells resistant to range of targeted cancer treatments vulnerable to these treatments again. In addition it also works as a therapy in a range of tumours in its own right. The SME is looking to partner with larger pharmaceutical companies for first in human and clinical trials. It is envisaged that the partnership will be either a joint venture or a licensing agreement.
Cancer is the second leading cause of death globally despite great strides being made in both the detection and treatment of the disease. One of the issues is resistance to first line chemotherapy developing.
A UK-based SME has developed a formulation based on well characterised chemical entities that unmasks key sites on tumour cells making them more vulnerable to a range of targeted cancer treatments and so overcoming the problem of resistance. It has also been shown to have its own activity as a mono therapy in a range of tumours. The formulation has generated promising data in pre-clinical studies and the SME is looking to move development forwards into first in human trials.
The SME is looking to partner with a larger pharmaceutical company operating in the field of oncology that would be able to carry out the first in human trials with a view to regulation and commercialisation of the formulation. It is envisaged that the partnership will take the form of a joint venture. Alternatively the UK SME will consider licensing the technology to the partner company if that better suits both parties.
The UK SME's formulation has the following advantages:
1. Inhibits the cell signalling pathways that lead to cancer development and progression.
2. Renders a range of targeted cancer treatments effective by unmasking key sites on tumour cells.
3. Has activity against a range of tumours as a mono therapy.
4. It testing carried out to date the formulation shows low toxicity and low level of side effects.
The UK SME is looking to partner with larger pharmaceutical companies operating in oncology sector. In particular the partner must be able to take the SMEs formulation from its current pre-clinical stage through first in human and preferably subsequent clinical trials to commercialisation.
The partnership is expected to take the form of either a joint venture or a licensing agreement, dependent on which is most beneficial to both parties.